Результаты поиска

Optimizing individualized therapy decision-making in multiple myeloma (MM): integration and impact of the Revised Myeloma Comorbidity Index in the MM-tumor board.

Multiple Myeloma (MM) is a hematological disease predominantly affecting elderly patients. The complexity of current treatment necessitates individualized approaches. Therein, functional assessment (FA) tools, such as the Revised Comorbidity Index (R-MCI) at our University- and Comprehensive Cancer Center Freiburg, play a crucial role. This study aimed to determine (a) the implementation of the R-MCI in our MM-tumor board (MM-TB), (b) its impact on treatment guidance at baseline and (c) potential changes during follow-up. This exploratory study investigated R-MCI coverage and distribution in a

Доказательства потенциала гуанидов против Leishmania (Viannia) braziliensis: исследование витро эффективности, токсичности и влияния на ответ иммунной системы.

Лейшманиаз — это сложная группа инфекционных и паразитарных заболеваний, которая поражает десятки тысяч людей на пяти континентах. Лечение лейшманиаза остается сложной задачей, так как оно зависит от лекарств, известных своей высокой токсичностью и ограниченной эффективностью, что делает необходимым поиск новых молекул, которые обеспечивали бы большую эффективность и безопасность. Настоящее исследование посвящено изучению влияния семи синтетических гуанидиновых производных (LQOF-G1, LQOF-G2, LQOF-G6, LQOF-G7, LQOF-G32, LQOF-G35 и LQOF-G36) на паразита Leishmania (Viannia) braziliensis и витроп

Качество жизни многих пациентов с миеломой, прошедших курс лечения с высоким или низким содержанием леналидомида после автономной трансплантации стволовых клеток в ходе испытания на Ленамаин (LenaMain)NCT00891384).

ВВЕДЕНИЕ: Судебный процесс по делу Ленамаина (LenaMain)NCT00891384) сообщили об увеличении безподвижного выживания с 25 мг содержания линалидомида по сравнению с 5 мг. Здесь мы сообщаем о результатах, о которых сообщили пациенты. МАТЕРИАЛЫ И МЕТОДЫ: Были проанализированы оценки, полученные на основе вопросника C30 EORTC " Качество жизни " , на предмет продольных изменений исходных условий в рамках групп, а также перекрестных оценок. Результаты: показатели соблюдения были высокими, при этом 95.7% на исходном уровне и 70% в ходе технического обслуживания. При поступлении в школу оценки

Epidemiology, genetics and treatment of multiple myeloma and precursor diseases.

Multiple myeloma (MM) is a hematological malignancy caused by the clonal expansion of plasma cells. The incidence of MM worldwide is increasing with greater than 140 000 people being diagnosed with MM per year. Whereas 5-year survival after a diagnosis of MM has improved from 28% in 1975 to 56% in 2012, the disease remains essentially incurable. In this review, we summarize our current understanding of MM including its epidemiology, genetics and biology. We will also provide an overview of MM management that has led to improvements in survival, including recent changes to diagnosis and therapi

Pharmacokinetics and outcome of high-dose melphalan followed by autologous stem cell transplantation in dialysis-dependent patients with multiple myeloma.

High-dose melphalan followed by autologous stem cell transplantation (ASCT) remains the standard of care for fit patients with multiple myeloma (MM). However, individuals who are dependent on hemodialysis are frequently excluded from ASCT. Recommendations on chemotherapy dosing and hemodialysis scheduling vary in literature and definite conclusions are impeded by the heterogeneity of cohorts. We aimed to evaluate the safety and efficacy of ASCT in patients with MM and end-stage renal disease and to examine the pharmacokinetics of melphalan on a fixed schedule of melphalan infusion and hemodial

Case Report: AL Amyloidosis Severe Restrictive Cardiomyopathy Associated With Multiple Myeloma-Diagnostic Difficulties.

BackgroundCardiac AL amyloidosis as a complication of multiple myeloma (MM) is a formidable life-threatening condition. The first-line therapy for both MM and systemic AL amyloidosis is proteasome inhibitors (PIs). Unfortunately, the use of PIs may lead to cardiovascular toxicity development, which requires specific cardio-oncology supervision.Case reportA 57-year-old woman was admitted to a university hospital with clinical manifestation of progressive chronic heart failure. The patient had hypertension and no history of diabetes mellitus, myocardial infarction (MI), stroke, and arrhythmias.

Real World Efficacy and Safety Results of Ixazomib Lenalidomide and Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program.

Ixazomib-Revlimid-Dexamethasone is an all-oral treatment protocol for multiple myeloma with a manageable tolerability profile which was available through a named patient program for Hungarian patients from December 2015 to April 2017. We analyzed the clinical characteristics and survival of 77 patients treated at 7 centers within this program. The majority of patients responded, we found complete response in 9, very good partial response in 8, partial response in 32, minor response or stable disease in 13 and progressive disease in 11 patients. Progression free survival was 11.4 months. There

Adverse Hematological and Non-Hematological Events in Patients With Relapsed/Refractory Multiple Myeloma That Are Responsive to Daratumumab, Pomalidomide and Dexamethasone.

BackgroundDaratumumab, pomalidomide, and dexamethasone (DPd) is an effective option for treatment of patients with relapsed/refractory multiple myeloma (RRMM). In this study, we sought to analyze the risk of hematological and non-hematological toxicities in patients who responded to DPd treatment.MethodsWe analyzed 97 patients with RRMM who were treated with DPd between January 2015 and June 2022. The patients and disease characteristics, as well as safety and efficacy outcomes were summarized as descriptive analysis.ResultsThe overall response rate for the entire group was 74% (n = 72). The m

Psychiatric morbidity and poor follow-up underlie suboptimal functional and survival outcomes in Huntington's disease.

BackgroundHuntington's disease (HD), an inherited, often late-onset, neurodegenerative disorder, is considered to be a rare, orphan disease. Research into its genetic correlates and services for those affected are inadequate in most low-middle income countries, including India. The apparent 'incurability' often deters symptomatic and rehabilitative care, resulting in poor quality of life and sub-optimal outcomes. There are no studies assessing disease burden and outcomes from India.MethodsWe attempted to evaluate individuals diagnosed to have HD at our tertiary-care center between 2013 and 201

Анализ экономической эффективности даратумумаба плюс бортезомиба, мелфалана и преднизона против бортезомиба, мелфалана и преднизона у пациентов с недавно поставленным диагнозом множественной миеломы, не имеющей права на трансплантацию стволовых клеток.

Цель этого исследования заключалась в изучении экономической эффективности бортезомиба, мелфалана и преднизона с использованием даратумумаба (D-VMP) против борцезомиба, мелфалана и преднизона (VMP) у пациентов с недавно поставленным диагнозом множественной миеломы (NDMM), которые были лишены права на автоматическую трансплантацию стволовых клеток (ASCT). Была разработана модель MetodsA Маркова и three Включены только состояние здоровья, отсутствие прогресса в выживании (ПФС), прогрессивные заболевания (ПЗ) и смерть. Продолжительность цикла была установлена следующим образом: 1.5 месяцев и врем

Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM).

Background and Objectives: Ixazomib, used in combination with lenalidomide and dexamethasone (IRd), has shown efficacy in clinical trials for relapsed/refractory multiple myeloma (RRMM). Materials and Methods: This study evaluates the real-world effectiveness and safety of IRd in Croatian RRMM patients. A retrospective analysis was conducted on 164 RRMM patients treated with ixazomib at nine Croatian haematology centres from November 2016 to February 2023. Data on patient demographics, treatment regimens, and outcomes were collected and analysed using Kaplan-Meier survival curves and Cox propo

Совпадение в полном тексте источника
… Triplet combinations in relapsed/refractory myeloma: Update on recent phase 3 trials. Expert Rev. Hematol. 2017;10:207–215. doi: 10.1080/17474086.2017.1285694. 3. Dimopoulos M.A., Moreau P., Terpos E., Mateos M.V., Zweegman S., Cook G., Delforge M., Hájek R., Schjesvold F., Cavo M., et al. … Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US. Ann. Hematol. 2021;100:2325–2337. doi: 10.1007/s00277-021-04534-8. 15. …

Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003).

Pomalidomide has been shown to improve survival in patients with relapsed/refractory myeloma (RRMM). However, the optimal pomalidomide-based combinations in RRMM are not known. This study compared pomalidomide, cyclophosphamide, dexamethasone (PCD) with pomalidomide and dexamethasone (PD) in Asian patients with RRMM. Patients were randomly assigned to receive PCD or PD. Patients received pomalidomide at 4 mg from days 1 to 21, dexamethasone at 40 mg once a week, and those in the PCD arm received cyclophosphamide at 400 mg once weekly for three weeks. The primary endpoint was progression-free s

Клинические характеристики, лабораторные меры и качество жизни как предвестники соблюдения лекарств в множестве миеломы.

Соблюдение лекарств в миеломе (ММ) является одним из ключевых факторов, определяющих результаты лечения, однако его взаимосвязь с качеством жизни, о котором сообщают пациенты, по-прежнему недостаточно изучена. Мы провели многоцентральное перекрестное исследование по всему спектру five Больницы на Западном берегу2018–2025), зачисление 250 Взрослые с MM на активном лечении. При поступлении в школу пациенты закончили ЭОРТК QLQ-MY20 для оценки КОЛ для конкретных заболеваний, и one Месяц спустя была проведена оценка участия в программе с использованием Moricy Mediction. Scale-4 (В тыс.MMAS-4). Боль

Совпадение в полном тексте источника
… Among treatment regimens, bortezomib-based triplets remain a key component of multiple myeloma therapy. … To ensure accurate verification of full triplet administration, we performed cycle-level tracking of each component of the regimen. …

Emerging agents and regimens for multiple myeloma.

The outcomes of multiple myeloma (MM) have been improved significantly with the therapies incorporating proteasome inhibitors (PI), immunomodulatory drugs, monoclonal antibodies (MoAb) and stem cell transplantation. However, relapsed and refractory MM (RRMM) remains a major challenge. Novel agents and regimens are under active clinical development. These include new PIs such as ixazomib, marizomib, and oprozomib; new MoAbs such as isatuximab and MOR202; novel epigenetic agent ricolinostat and novel cytokines such as siltuximab. Recently, the first XPO-1 inhibitor, selinexor, was approved for R

Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review.

For patients with newly diagnosed multiple myeloma, survival outcomes continue to improve significantly: however, nearly all patients will relapse following induction treatment. Optimisation of induction therapy is essential to provide longer term disease control and the current standard of care for most patients incorporates an immunomodulatory agent and proteasome inhibitor, most commonly lenalidomide and bortezomib in combination with dexamethasone (RVD), with maintenance until progression. Historically there has been limited access to RVD as an induction strategy outside of the United Stat

Совпадение в полном тексте источника
… In those jurisdictions with access, DRd and D‐VMP are alternative triplets that may be utilised in the transplant‐ineligible population. … Due to higher rates of toxicity and drug discontinuation in older patients, 48 we utilise attenuated RVD regimens in transplant‐ineligible patients deemed suitable for triplet therapy. …

Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?

The treatment landscape for multiple myeloma (MM) is evolving with our understanding of its pathophysiology. However, given the inevitable cohort heterogeneity in salvage therapy, response to treatment and overall prognoses tend to vary widely, making meaningful conclusions about treatment efficacy difficult to derive. Despite the hurdles in current research, progress is underway toward more targeted therapeutic approaches. Several new drugs with novel mechanism of action and less toxic profile have been developed in the past decade, with the potential for use as single agents or in synergy wi

PB1998: WEEKLY OPPOSED TO BI-WEEKLY BORTEZOMIB AS PART OF INDUCTION CHEMOTHERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA IS BETTER TOLERATED AND EQUALLY EFFICIENT: REAL-WORLD DATA FROM A RETROSPECTIVE AUDIT

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Ex Vivo Treatment Response Prediction in Multiple Myeloma: Assay Formats, Clinical Correlation, and Future Directions.

Ex vivo functional testing for multiple myeloma is rapidly evolving, yet no single assay has reached the level of reliability and clinical utility needed for routine decision-making. Existing approaches generally fall into three categories: 2D cultures, 3D models, and dynamic systems. Each contributes valuable but incomplete insight into therapeutic response. Among these, 2D assays remain the most mature, with the most extensive clinical correlations to date, though their simplified architecture limits their ability to reflect the full complexity of the bone marrow microenvironment. However, 3

Amyloidosis due to TTR mutations in Mexico with 4 distincts genotypes in the index cases.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

P46 SEER-MEDICARE DATABASE: REAL-WORLD TREATMENTS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED MULTIPLE MYELOMA TREATED WITH 1–3 PRIOR LINES OF THERAPY, INCLUDING A PI AND IMID

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.